{"status": "ok", "totalResults": 84, "articles": [{"source": {"id": "al-jazeera-english", "name": "Al Jazeera English"}, "author": "Al Jazeera", "title": "India bans hundreds of combination drugs", "description": "Government outlaws 328 drugs to combat medicine misuse and rising antibiotic resistance.", "url": "https://www.aljazeera.com/news/2018/09/india-bans-hundreds-combination-drugs-180913085744857.html", "urlToImage": "https://www.aljazeera.com/mritems/Images/2018/9/13/21551545769d41bbae79f1cdcdbd2ee5_18.jpg", "publishedAt": "2018-09-13T10:39:01Z", "content": "The Indian government has banned 328 combination drugs in a blow to both domestic and foreign pharmaceutical firms, but the ban has been cheered by health activists worried about growing antibiotic resistance due to the misuse of medicines. The Indian governm\u2026 [+1954 chars]"}, {"source": {"id": null, "name": "Indianexpress.com"}, "author": "PTI", "title": "Centre bans 328 combination drugs in setback for pharma companies", "description": "The president of the Indian Drug Manufacturers' Association said the order would have an impact on a market worth an estimated 16 billion rupees a year for such drugs, which are produced by both small and large pharma companies.", "url": "https://indianexpress.com/article/business/business-others/centre-bans-328-combination-drugs-in-setback-for-pharma-companies-5354509/", "urlToImage": "https://images.indianexpress.com/2017/11/drugs-7592.jpg?w=759", "publishedAt": "2018-09-13T09:13:42Z", "content": "By: PTI | New Delhi | Published: September 13, 2018 2:43:42 pm Combination drugs are used to improve patients\u2019 compliance, as it is easier to get patients to take one drug rather than several. (Representational image) The Indian government has banned 328 comb\u2026 [+2241 chars]"}, {"source": {"id": "reuters", "name": "Reuters"}, "author": "Reuters Editorial", "title": "India bans 328 combination drugs in setback for pharma companies", "description": "The Indian government has banned 328 combination drugs in a blow to both domestic and foreign pharmaceutical firms, but the ban has been cheered by health activists worried about growing antibiotic resistance due to the misuse of medicines.", "url": "https://www.reuters.com/article/us-india-health-drugs/india-bans-328-combination-drugs-in-setback-for-pharma-companies-idUSKCN1LT155", "urlToImage": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "publishedAt": "2018-09-13T08:39:28Z", "content": "NEW DELHI (Reuters) - The Indian government has banned 328 combination drugs in a blow to both domestic and foreign pharmaceutical firms, but the ban has been cheered by health activists worried about growing antibiotic resistance due to the misuse of medicin\u2026 [+2034 chars]"}, {"source": {"id": "the-hindu", "name": "The Hindu"}, "author": "Special Correspondent", "title": "NORD plans to set up assembling plant in State", "description": "Markets in India have big scope: MD", "url": "https://www.thehindu.com/news/cities/Visakhapatnam/nord-plans-to-set-up-assembling-plant-in-state/article24897488.ece", "urlToImage": "https://www.thehindu.com/static/theme/default/base/img/og-image.jpg", "publishedAt": "2018-09-07T19:31:40Z", "content": "Mechanical and electrical solutions manufacturer NORD Drive Systems, a subsidiary of Germany-based Getriebebau NORD, organised an end-user service conference and a road show, in association with the AP Chambers of Commerce and Industry Federation (APCCIF) her\u2026 [+1092 chars]"}, {"source": {"id": null, "name": "Moneycontrol.com"}, "author": null, "title": "Lupin to train over 1,000 graduates for pharma industry by 2020", "description": "Lupin has launched its #39;Learn and Earn#39; initiative in which candidate who has passed Standard 12 in the science stream with a minimum of 50 percent marks but are facing financial constraints are taken for three-year-long course during which they are pai\u2026", "url": "https://www.moneycontrol.com/news/business/lupin-to-train-over-1000-graduates-for-pharma-industry-by-2020-2924881.html", "urlToImage": "https://static-news.moneycontrol.com/static-mcnews/2018/07/Lupin-770x433.jpg", "publishedAt": "2018-09-06T10:46:05Z", "content": "Pharmceutical giant, Lupin Limited expects to train more than 1,000 under graduates into pharma professionals by the year 2020 under its Learn and Earn Initiative, a senior company official said today. Lupin has launched its 'Learn and Earn' initiative in whi\u2026 [+1850 chars]"}, {"source": {"id": null, "name": "Insightsonindia.com"}, "author": "InsightsIAS", "title": "Insights into Editorial: Biosimilars need huge investments, longer timelines", "description": "Insights into Editorial: Biosimilars need huge investments, longer timelines What are Biosimilars? A biosimilar is a biologic medical product that is almost an identical copy of an original product that is manufactured by a different company. Biosimilars are \u2026", "url": "http://www.insightsonindia.com/2018/09/07/insights-into-editorial-biosimilars-need-huge-investments-longer-timelines/", "urlToImage": "http://www.insightsonindia.com/wp-content/uploads/2018/09/editorial-2.jpg", "publishedAt": "2018-09-07T03:41:45Z", "content": "Insights into Editorial: Biosimilars need huge investments, longer timelines What are Biosimilars? A biosimilar is a biologic medical product that is almost an identical copy of an original product that is manufactured by a different company. Biosimilars are \u2026 [+5142 chars]"}, {"source": {"id": "the-times-of-india", "name": "The Times of India"}, "author": "Jimeet Modi", "title": "'Towards correction and selective profit taking'", "description": "Uncertainty is likely to persist and the downward drift might not ease anytime soon.", "url": "https://economictimes.indiatimes.com/markets/stocks/news/journey-towards-correction-begins-its-time-for-selective-profit-taking/articleshow/65729453.cms", "urlToImage": "https://img.etimg.com/thumb/msid-65729478,width-1070,height-580,imgsize-53614,overlay-etmarkets/photo.jpg", "publishedAt": "2018-09-08T05:33:34Z", "content": "Mr Market finally made a top during the week gone by and started correcting in response to the local and global tailwinds, primarily due to a strengthening dollar, growing current account deficit, inflationary expectations, global tightening and worsening geo\u2026 [+3224 chars]"}, {"source": {"id": null, "name": "Dailycaller.com"}, "author": "Mark Anthony", "title": "Drug Proposal Could Be Major Job Creator In India, China", "description": "Experts say American consumers may end up facing increased risks when buying medicines", "url": "https://dailycaller.com/2018/09/06/major-job-creator-in-india-china/", "urlToImage": "https://cdn01.dailycaller.com/wp-content/uploads/2018/09/1004465254-594x594-e1536261929709.jpg", "publishedAt": "2018-09-06T19:25:48Z", "content": "Drug companies in India and China are drooling over the prospect that many American jobs in the pharmaceutical industry could soon be outsourced overseas. The reason? A recent announcement from the U.S. Food and Drug Administration (FDA) that it is exploring \u2026 [+3702 chars]"}, {"source": {"id": null, "name": "Channelnewsasia.com"}, "author": null, "title": "India bans 328 combination drugs in setback for pharma companies", "description": "NEW DELHI: The Indian government has banned 328 combination drugs in a blow to both domestic and foreign pharmaceutical firms, but the ban has been cheered by health activists worried about growing antibiotic resistance due to the misuse of medicines. The Ind\u2026", "url": "https://www.channelnewsasia.com/news/asia/india-bans-328-combination-drugs-in-setback-for-pharma-companies-10717982", "urlToImage": "http://www.channelnewsasia.com/image/10102260/16x9/991/557/4d1de7be91072f792c7176fba6c7b2c6/Ho/asia-new-default-image.png", "publishedAt": "2018-09-13T08:41:27Z", "content": "NEW DELHI: The Indian government has banned 328 combination drugs in a blow to both domestic and foreign pharmaceutical firms, but the ban has been cheered by health activists worried about growing antibiotic resistance due to the misuse of medicines. The Ind\u2026 [+2069 chars]"}, {"source": {"id": null, "name": "Tribune.com.pk"}, "author": "Reuters, Hasnaat Mailk, Our Correspondent, Our Correspondent, Our Correspondent, Entertainment Desk, Reuters, Reuters, Rahul Aijaz", "title": "India bans 328 combination drugs in setback for pharma companies", "description": "Indian government had in 2016 banned about 350 such drugs The post India bans 328 combination drugs in setback for pharma companies appeared first on The Express Tribune.", "url": "https://tribune.com.pk/story/1802287/3-india-bans-328-combination-drugs-setback-pharma-companies/", "urlToImage": "https://c.tribune.com.pk/2018/09/1802287-pillsmedicinedrugsxcopyx-1536831784-675-640x480.jpg", "publishedAt": "2018-09-13T09:49:23Z", "content": "India bans 328 combination drugs. PHOTO: AFP NEW DELHI: The Indian government has banned 328 combination drugs in a blow to both domestic and foreign pharmaceutical firms, but the ban has been cheered by health activists worried about growing antibiotic resis\u2026 [+2134 chars]"}, {"source": {"id": null, "name": "Livemint.com"}, "author": "Atanu Biswas", "title": "Opinion | The importance of trials in stem cell drugs", "description": "There are self-styled clinics in India offering a range of untested and unproven stem cell drugs", "url": "https://www.livemint.com/Opinion/SEgFFsnMhqRbChyCPw8rfO/Opinion--The-importance-of-trials-in-stem-cell-drugs.html", "urlToImage": "https://www.livemint.com/rf/Image-621x414/LiveMint/Period2/2018/09/13/Photos/Home%20Page/stemcell-kQu--621x414@LiveMint.jpg", "publishedAt": "2018-09-12T17:14:50Z", "content": "The new amendments to the Drugs and Cosmetics Rules of India will be in effect from 13 September. Due to several controversies, allegations of irregularities and protests by health workers against the consent and compensation policies for people undergoing cl\u2026 [+5138 chars]"}, {"source": {"id": null, "name": "Ip-watch.org"}, "author": "Intellectual Property Watch", "title": "Inside Views: Brazilian Supreme Court Refuses To Judge Its Biggest Case On IP And Access To Medicines, And Benefits Big Pharma With Undue Monopolies", "description": "The Brazilian Supreme Court (STF) has mysteriously cancelled the judgment of the most important case regarding intellectual property and health ever to be decided by the court. On 28 June, the date of the judgment was set for 6 September. The cancellation occ\u2026", "url": "http://www.ip-watch.org/2018/09/13/brazilian-supreme-court-refuses-judge-biggest-case-ip-access-medicines-benefits-big-pharma-undue-monopolies/", "urlToImage": "http://media.ip-watch.org/weblog/wp-content/uploads/2018/09/Brazil-Carmem-Lucia-w-pharma-300x200.jpg?6e9db4", "publishedAt": "2018-09-13T13:55:56Z", "content": "By Marcela Foga\u00e7a Vieira and Pedro Villardi The Brazilian Supreme Court (STF) has mysteriously cancelled the judgment of the most important case regarding intellectual property and health ever to be decided by the court. On 28 June, the date of the judgment w\u2026 [+15719 chars]"}, {"source": {"id": null, "name": "Insightsonindia.com"}, "author": "InsightsIAS", "title": "SECURE SYNOPSIS: 04 SEPTEMBER 2018", "description": "SECURE SYNOPSIS: 04 SEPTEMBER 2018 NOTE: Please remember that following \u2018answers\u2019 are NOT \u2018model answers\u2019. They are NOT synopsis too if we go by definition of the term. What we are providing is content that both meets demand of the question and at the same ti\u2026", "url": "http://www.insightsonindia.com/2018/09/10/secure-synopsis-04-september-2018/", "urlToImage": "http://www.insightsonindia.com/wp-content/uploads/2018/09/6-2.jpg", "publishedAt": "2018-09-10T09:24:47Z", "content": "SECURE SYNOPSIS: 04 SEPTEMBER 2018 NOTE: Please remember that following \u2018answers\u2019 are NOT \u2018model answers\u2019. They are NOT synopsis too if we go by definition of the term. What we are providing is content that both meets demand of the question and at the same ti\u2026 [+49807 chars]"}, {"source": {"id": null, "name": "Iasexamportal.com"}, "author": "trainee5", "title": "THE GIST of Editorial for UPSC Exams : 13 September 2018 (The importance of trials in stem cell drugs)", "description": "The importance of trials in stem cell drugs Mains Paper: 2 | Health Prelims level: stem cell drugs Mains level: India offering a range of untested and unproven stem cell drugs. Introduction The Federation of Asian Biotech Associations forecast an annual growt\u2026", "url": "https://iasexamportal.com/editorial-gist/13-09-2018-the-importance-of-trials-in-stem-cell-drugs?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+upscportal+%28IAS+EXAM+PORTAL++-+India%27s+Largest+IAS%2C+IFS%2C+PCS%2C+Civil+Services+Aspirants+Community.%29", "urlToImage": null, "publishedAt": "2018-09-13T11:21:45Z", "content": "The importance of trials in stem cell drugs Mains Paper: 2 | Health Prelims level: stem cell drugs Mains level: India offering a range of untested and unproven stem cell drugs. Introduction The Federation of Asian Biotech Associations forecast an annual growt\u2026 [+4182 chars]"}, {"source": {"id": null, "name": "Prnewswire.com"}, "author": null, "title": "E-Clinical Trials Market Growth Driven by Rising R&D Spending by Pharma-Biotech Companies for Innovative Drug Development: Radiant Insights, Inc.", "description": "SAN FRANCISCO, September 11, 2018 /PRNewswire/ -- Global E-clinical Trials Market is expected to grow at a significant CAGR in the upcoming years as the scope and its applications are rising enormously across the globe. E-clinical Trials is termed as a trial \u2026", "url": "https://www.prnewswire.com/news-releases/e-clinical-trials-market-growth-driven-by-rising-r-amp-d-spending-by-pharma-biotech-companies-for-innovative-drug-development-radiant-insights-inc--871693114.html", "urlToImage": "/content/dam/prnewswire/common/prn_facebook_sharing_logo.jpg", "publishedAt": "2018-09-11T09:45:00Z", "content": "SAN FRANCISCO, September 11, 2018 /PRNewswire/ -- Global E-clinical Trials Market is expected to grow at a significant CAGR in the upcoming years as the scope and its applications are rising enormously across the globe. E-clinical Trials is termed as a trial \u2026 [+5126 chars]"}, {"source": {"id": "independent", "name": "Independent"}, "author": "Rob Merrick, Rob Merrick", "title": "UK taxpayers to foot bill for stockpiling medicines to prepare for no-deal Brexit", "description": "'We are talking to the pharmaceutical industry about the extra cost that they might have to incur,' Matt Hancock says", "url": "https://www.independent.co.uk/news/uk/politics/no-deal-brexit-medicine-stockpile-taxpayers-nhs-matt-hancock-a8525051.html", "urlToImage": "https://static.independent.co.uk/s3fs-public/thumbnails/image/2017/11/15/13/medicines.png", "publishedAt": "2018-09-06T08:11:42Z", "content": "Taxpayers will have to foot the bill for stockpiling NHS medicines to prepare for crashing out of the EU without a deal, the health secretary says. Matt Hancock revealed he was \u201ctalking to pharmaceutical industry about what extra costs the government should c\u2026 [+9743 chars]"}, {"source": {"id": null, "name": "Thehindubusinessline.com"}, "author": "Rajiv Nath", "title": "Profit-making device", "description": "No level-playing field in medical devices market", "url": "https://www.thehindubusinessline.com/opinion/columns/profit-making-device/article24884323.ece", "urlToImage": "https://www.thehindubusinessline.com/opinion/columns/4ppz1h/article24884321.ece/ALTERNATES/LANDSCAPE_615/BL07THINKMED1", "publishedAt": "2018-09-06T15:37:07Z", "content": "Rajiv Nath The Global Healthcare Access and Quality Index (2018) ranks India at 145 among 190 nations, lower than Bangladesh, Sudan and Equatorial Guinea. This ranking should drive the authorities and industry to change this landscape by ensuring affordable a\u2026 [+3231 chars]"}, {"source": {"id": "reuters", "name": "Reuters"}, "author": "Ben Hirschler", "title": "EU officials clash with Chinese firm on drug factory inspection", "description": "European medicines regulators have issued a notice that an ingredient for a generic brain cancer drug made in China does not meet manufacturing standards, after inspectors were refused entry to a factory run by Jiangsu Yew Pharmaceutical Co. Ltd.", "url": "https://www.reuters.com/article/health-pharmaceuticals-china/eu-officials-clash-with-chinese-firm-on-drug-factory-inspection-idUSL5N1VY4IV", "urlToImage": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "publishedAt": "2018-09-12T13:40:43Z", "content": "LONDON, Sept 12 (Reuters) - European medicines regulators have issued a notice that an ingredient for a generic brain cancer drug made in China does not meet manufacturing standards, after inspectors were refused entry to a factory run by Jiangsu Yew Pharmace\u2026 [+1606 chars]"}, {"source": {"id": null, "name": "Seekingalpha.com"}, "author": "SA Transcripts", "title": "Lakeland Industries, Inc. (LAKE) CEO Christopher Ryan on Q2 2019 Results - Earnings Call Transcript", "description": "Lakeland Industries, Inc. (NASDAQ:LAKE) Q2 2019 Earnings Conference Call September 10, 2018 04:30 PM ET Executives Christopher Ryan - Chief Executive Officer Te", "url": "https://seekingalpha.com/article/4205429-lakeland-industries-inc-lake-ceo-christopher-ryan-q2-2019-results-earnings-call-transcript", "urlToImage": "https://static3.seekingalpha.com/assets/og_image_192-59bfd51c9fe6af025b2f9f96c807e46f8e2f06c5ae787b15bf1423e6c676d4db.png", "publishedAt": "2018-09-11T00:16:05Z", "content": "Lakeland Industries, Inc. (NASDAQ: LAKE ) Q2 2019 Earnings Conference Call September 10, 2018 4:30 PM ET Executives Christopher Ryan - Chief Executive Officer Teri Hunt - Chief Financial Officer Analysts Dave King - ROTH Capital Alex Fuhrman - Craig-Hallum Ca\u2026 [+29460 chars]"}, {"source": {"id": null, "name": "Thehindubusinessline.com"}, "author": "Shobha Roy", "title": "NetMeds to set up brick-and-mortar pharmacies", "description": "Shobha RoyOnline pharmacy marketplace NetMeds is looking to set up offline stores to cater to tier II, III and IV markets. According to Pradeep Dadha", "url": "https://www.thehindubusinessline.com/companies/netmeds-to-set-up-brick-and-mortar-pharmacies/article24908170.ece", "urlToImage": "https://www.thehindubusinessline.com/companies/9vxssk/article24908169.ece/ALTERNATES/LANDSCAPE_615/Mr%20Pradeep%20Dadha%20Founder%20and%20CEO%20Netmedscom", "publishedAt": "2018-09-09T11:17:43Z", "content": "Shobha Roy Online pharmacy marketplace NetMeds is looking to set up offline stores to cater to tier II, III and IV markets. According to Pradeep Dadha, founder and CEO, a pilot project is under way to \u2018understand and evaluate\u2019 the offline model. \u201cIn three mon\u2026 [+1862 chars]"}]}